Athens University Medical School, 1st Department of Psychiatry, Eginition Hospital, Athens, Greece.
Int J Clin Pract. 2013 Mar;67(3):257-60. doi: 10.1111/ijcp.12112.
The present study compared the efficacy of agomelatine and sertraline in the treatment of symptoms of depression/anxiety, diabetes self-care and metabolic control in a sample of depressed patients with non-optimally controlled type 2 diabetes mellitus (DM).
This was an observational open label study of 40 depressed patients with DM who were randomly assigned to receive either agomelatine or sertraline, and were assessed over a 4-month period for depression, anxiety, self-care, fasting plasma glucose, haemoglobin A1c and body weight.
Lower anxiety and depression scores as well as higher self-care scores were measured in the agomelatine group compared with the sertraline group after 4 months of treatment. Although the main effects of treatment on final body weight and fasting plasma glucose were not significant, significantly lower final haemoglobin A1c levels were measured in the agomelatine group compared with the sertraline group. Both antidepressants were well tolerated and none of the patients dropped-out of the study.
The main finding of the present small pilot study was that agomelatine may be a promising agent in the treatment of symptoms of depression and anxiety as well as in the improvement of health-related behaviours, in depressed patients with type 2 DM possibly offering some advantages over sertraline. However, the lack of a placebo control group limits the generalisability of the findings and warrants further studies.
本研究比较了阿戈美拉汀和舍曲林在治疗伴有 2 型糖尿病（DM）血糖控制不佳的抑郁患者的抑郁/焦虑症状、糖尿病自我护理和代谢控制方面的疗效。
这是一项观察性、开放标签的研究，共纳入 40 例抑郁合并 DM 的患者，随机分为阿戈美拉汀组或舍曲林组，在 4 个月的时间内评估抑郁、焦虑、自我护理、空腹血糖、糖化血红蛋白和体重。
治疗 4 个月后，阿戈美拉汀组的焦虑和抑郁评分较低，自我护理评分较高。虽然治疗对最终体重和空腹血糖的主要影响不显著，但阿戈美拉汀组的最终糖化血红蛋白水平明显低于舍曲林组。两种抗抑郁药均耐受良好，无患者退出研究。
本小型初步研究的主要发现是，阿戈美拉汀可能是一种有前途的治疗 2 型糖尿病合并抑郁患者的抑郁和焦虑症状以及改善与健康相关行为的药物，在改善健康相关行为方面可能优于舍曲林。然而，缺乏安慰剂对照组限制了研究结果的普遍性，需要进一步研究。
